West Pharmaceutical Services, Inc. (NYSE:WST) Surpasses Earnings and Revenue Estimates
- West Pharmaceutical Services, Inc. reported an EPS of $1.82, beating the estimated $1.71 and showcasing its ability to exceed expectations.
- The company achieved a revenue of approximately $748.8 million, surpassing both the estimated $716.75 million and the Zacks Consensus Estimate by 1.25%.
- WST's financial health is solid with a debt-to-equity ratio of 0.11 and a current ratio of 3.00, indicating low debt levels and strong short-term financial stability.
West Pharmaceutical Services, Inc. is a key player in the medical and dental supplies industry, specializing in the design and manufacture of innovative solutions for injectable drug administration. Competing with other industry giants, WST focuses on providing high-quality products that meet the needs of healthcare providers and patients worldwide.
On February 13, 2025, WST reported earnings per share (EPS) of $1.82, surpassing the estimated $1.71. This performance also exceeded the Zacks Consensus Estimate of $1.75, marking a 4% earnings surprise. Although slightly lower than the $1.83 EPS from the previous year, WST has consistently outperformed expectations, exceeding consensus EPS estimates in three of the last four quarters.
WST achieved a revenue of approximately $748.8 million, surpassing the estimated $716.75 million. This revenue also exceeded the Zacks Consensus Estimate by 1.25%, showing growth from the $732 million reported in the same quarter the previous year. The company has consistently surpassed consensus revenue estimates in three of the last four quarters, highlighting its strong market position.
The company's financial metrics reflect its valuation and financial health. With a price-to-earnings (P/E) ratio of approximately 47, investors are willing to pay $47 for every $1 of earnings. The price-to-sales ratio is about 8.11, and the enterprise value to sales ratio is around 8.05, indicating a high valuation relative to sales. The enterprise value to operating cash flow ratio is approximately 32.96, showing how many times the operating cash flow can cover the enterprise value.
WST maintains a strong financial position with a debt-to-equity ratio of 0.11, indicating low debt levels compared to equity. The current ratio of 3.00 suggests that the company has three times more current assets than current liabilities, reflecting strong short-term financial health. The earnings yield of about 2.13% represents the percentage of each dollar invested that was earned by the company, providing insight into its profitability.
| Symbol | Price | %chg |
|---|---|---|
| 7741.T | 17500 | 0 |
| OMED.JK | 180 | 0 |
| 4543.T | 2563.5 | 0 |
| MARK.JK | 660 | 0 |
West Pharmaceutical Services, Inc. (WST) Financial Overview and Stock Performance
- West Pharmaceutical Services, Inc. (NYSE:WST) faces a decline in analysts' expectations with a current price target of $245, down from $319.
- Recent financial disclosures reveal challenges, including destocking in its High-Value Products portfolio and operational inefficiencies, impacting stock performance.
- Investors are advised to watch for the upcoming second-quarter financial results on July 24, 2025, amidst ongoing investigations by Faruqi & Faruqi, LLP for potential federal securities law violations.
West Pharmaceutical Services, Inc. (NYSE:WST) is a key player in the healthcare industry, specializing in containment and delivery systems for injectable drugs. The company operates through two main segments: Proprietary Products and Contract-Manufactured Products. It serves a diverse clientele, including pharmaceutical, biologic, and medical device companies. Founded in 1923, West is headquartered in Exton, Pennsylvania.
The current consensus price target for West is not explicitly stated, but recent data shows a stable short-term target of $245 over the last month and quarter. This stability suggests that analysts' expectations for West have not shifted significantly in the short term. UBS, however, has set a slightly higher price target of $250, indicating some positive expectations for the company's performance.
Over the past year, the average price target for West has declined from $319 to $245. This decline reflects a decrease in analysts' expectations for the stock. Several factors could contribute to this, including changes in market conditions, company performance, and industry trends. Notably, West's recent financial disclosures revealed challenges such as destocking in its High-Value Products portfolio and operational inefficiencies in its SmartDose device.
West's recent financial disclosures have impacted its stock performance. On February 13, 2025, the company issued weak revenue and earnings forecasts for the year, attributing the disappointing guidance to contract manufacturing headwinds. This included the loss of two major continuous glucose monitoring customers, leading to a significant stock price drop of $123.17 per share, closing at $199.11.
Investors should stay informed about West's upcoming second-quarter financial results, set to be released on July 24, 2025. The company will host a conference call to discuss these results and future business expectations. Additionally, Faruqi & Faruqi, LLP is investigating potential claims against West, alleging violations of federal securities laws. Investors are reminded of the July 7, 2025 deadline to seek the role of lead plaintiff in the class action.
West Pharmaceutical Services, Inc. (NYSE:WST) Earnings Preview: What to Expect
- West Pharmaceutical Services, Inc. (NYSE:WST) is set to release its first-quarter 2025 earnings with Wall Street anticipating an EPS of $1.22 and revenue projections of approximately $686.3 million.
- The company has a history of exceeding earnings expectations, with a track record of surpassing estimates three times in the last four quarters.
- Despite a projected year-over-year EPS decrease of 16.7%, WST's strong financial position is highlighted by a P/E ratio of 32.55 and a debt-to-equity ratio of 0.11, indicating resilience in a challenging market.
West Pharmaceutical Services, Inc. (NYSE:WST) is a key player in the pharmaceutical industry, specializing in the design and manufacture of innovative solutions for injectable drug administration. The company is known for its strong presence in the biologics and contract manufacturing sectors. As WST prepares to release its first-quarter 2025 earnings, investors are keenly watching the anticipated figures.
Wall Street estimates WST's earnings per share (EPS) to be $1.22, with projected revenue of approximately $686.3 million. However, the Zacks Consensus Estimate suggests a slightly higher EPS of $1.30 and revenue of $686.5 million. Despite these projections, internal estimates indicate a potential revenue of $686.2 million, reflecting a 1.1% organic growth from the previous year.
The company's performance in the previous quarter exceeded earnings expectations by 4%, and over the last four quarters, WST has surpassed earnings estimates three times, with an average surprise of 8.33%. This track record of exceeding expectations could influence investor sentiment positively if the upcoming results align with or surpass estimates.
Financially, WST maintains a strong position with a price-to-earnings (P/E) ratio of 32.55 and a price-to-sales ratio of 5.49. The company's low debt-to-equity ratio of 0.11 and a current ratio of 2.79 indicate a conservative capital structure and strong liquidity. These metrics suggest that WST is well-positioned to navigate potential market fluctuations following the earnings release.
West Pharmaceutical Services, Inc. (NYSE:WST) Earnings Preview: What to Expect
- West Pharmaceutical Services, Inc. (NYSE:WST) is set to release its first-quarter 2025 earnings with Wall Street anticipating an EPS of $1.22 and revenue projections of approximately $686.3 million.
- The company has a history of exceeding earnings expectations, with a track record of surpassing estimates three times in the last four quarters.
- Despite a projected year-over-year EPS decrease of 16.7%, WST's strong financial position is highlighted by a P/E ratio of 32.55 and a debt-to-equity ratio of 0.11, indicating resilience in a challenging market.
West Pharmaceutical Services, Inc. (NYSE:WST) is a key player in the pharmaceutical industry, specializing in the design and manufacture of innovative solutions for injectable drug administration. The company is known for its strong presence in the biologics and contract manufacturing sectors. As WST prepares to release its first-quarter 2025 earnings, investors are keenly watching the anticipated figures.
Wall Street estimates WST's earnings per share (EPS) to be $1.22, with projected revenue of approximately $686.3 million. However, the Zacks Consensus Estimate suggests a slightly higher EPS of $1.30 and revenue of $686.5 million. Despite these projections, internal estimates indicate a potential revenue of $686.2 million, reflecting a 1.1% organic growth from the previous year.
The company's performance in the previous quarter exceeded earnings expectations by 4%, and over the last four quarters, WST has surpassed earnings estimates three times, with an average surprise of 8.33%. This track record of exceeding expectations could influence investor sentiment positively if the upcoming results align with or surpass estimates.
Financially, WST maintains a strong position with a price-to-earnings (P/E) ratio of 32.55 and a price-to-sales ratio of 5.49. The company's low debt-to-equity ratio of 0.11 and a current ratio of 2.79 indicate a conservative capital structure and strong liquidity. These metrics suggest that WST is well-positioned to navigate potential market fluctuations following the earnings release.
West Pharmaceutical Services, Inc. (NYSE:WST) Surpasses Earnings and Revenue Estimates
- West Pharmaceutical Services, Inc. reported an EPS of $1.82, beating the estimated $1.71 and showcasing its ability to exceed expectations.
- The company achieved a revenue of approximately $748.8 million, surpassing both the estimated $716.75 million and the Zacks Consensus Estimate by 1.25%.
- WST's financial health is solid with a debt-to-equity ratio of 0.11 and a current ratio of 3.00, indicating low debt levels and strong short-term financial stability.
West Pharmaceutical Services, Inc. is a key player in the medical and dental supplies industry, specializing in the design and manufacture of innovative solutions for injectable drug administration. Competing with other industry giants, WST focuses on providing high-quality products that meet the needs of healthcare providers and patients worldwide.
On February 13, 2025, WST reported earnings per share (EPS) of $1.82, surpassing the estimated $1.71. This performance also exceeded the Zacks Consensus Estimate of $1.75, marking a 4% earnings surprise. Although slightly lower than the $1.83 EPS from the previous year, WST has consistently outperformed expectations, exceeding consensus EPS estimates in three of the last four quarters.
WST achieved a revenue of approximately $748.8 million, surpassing the estimated $716.75 million. This revenue also exceeded the Zacks Consensus Estimate by 1.25%, showing growth from the $732 million reported in the same quarter the previous year. The company has consistently surpassed consensus revenue estimates in three of the last four quarters, highlighting its strong market position.
The company's financial metrics reflect its valuation and financial health. With a price-to-earnings (P/E) ratio of approximately 47, investors are willing to pay $47 for every $1 of earnings. The price-to-sales ratio is about 8.11, and the enterprise value to sales ratio is around 8.05, indicating a high valuation relative to sales. The enterprise value to operating cash flow ratio is approximately 32.96, showing how many times the operating cash flow can cover the enterprise value.
WST maintains a strong financial position with a debt-to-equity ratio of 0.11, indicating low debt levels compared to equity. The current ratio of 3.00 suggests that the company has three times more current assets than current liabilities, reflecting strong short-term financial health. The earnings yield of about 2.13% represents the percentage of each dollar invested that was earned by the company, providing insight into its profitability.
